Summary
Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on January 30, 2019, primarily to disclose the release of its fourth quarter and full-year 2018 financial results and a significant operational update regarding its pharmacy benefit management (PBM) services. The company announced the termination of its PBM services agreement with Express Scripts, Inc., effective March 1, 2019. This strategic move indicates a shift in Elevance Health's approach to managing its prescription drug benefits, likely to bring these operations in-house or transition to a different provider, which could have substantial implications for cost management and operational control. The accompanying press release, furnished as an exhibit, would contain the detailed financial performance for the period ended December 31, 2018. Investors should pay close attention to the details within that press release (Exhibit 99.1) for specific earnings figures, revenue growth, profitability metrics, and any forward-looking guidance provided by the company. The termination of the Express Scripts contract is a major event that warrants careful consideration of its potential impact on future cost structures, service delivery, and overall financial performance.
Key Highlights
- 1Elevance Health (then Anthem, Inc.) announced the termination of its Pharmacy Benefits Management (PBM) services agreement with Express Scripts, Inc.
- 2The termination of the Express Scripts PBM agreement is effective March 1, 2019.
- 3The 8-K report includes financial results for the fourth quarter ended December 31, 2018, furnished via press release (Exhibit 99.1).
- 4The press release contains detailed financial results and potentially forward-looking statements regarding future performance.
- 5This action signals a significant strategic shift in how Elevance Health manages its prescription drug benefits.
- 6Investors are urged to review the press release (Exhibit 99.1) for comprehensive financial details and operational implications.